The randomized study lasted just 3 months, but researchers saw “multiple cardiometabolic benefits” beyond weight loss.

Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

Postmarket data on MitraClip lend further support to the idea that this subgroup fares as well as the overall SMR population.

Weekend warriors have a similarly low risk of disease and cardiometabolic health as those who spread exercise out evenly.

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

While promising, questions remain about sustained long-term benefits of cardiac myosin inhibitors and their impact on ...

With a much longer half-life than other radiotracers, flurpiridaz F-18 will boost patient access to PET imaging, one expert ...